Pfizer’s 6.3% Dividend and Low P/E Highlight GLP-1 Program Risks
Pfizer offers a 6.3% dividend yield and trades at a low P/E ratio compared with Eli Lilly’s 44, positioning it as undervalued despite stalled GLP-1 programs. Recent GLP-1 trial setbacks highlight development risks that contrast with Pfizer’s established revenue streams.
1. Market Position Versus Eli Lilly
Eli Lilly commands 56% of GLP-1 revenue with rapid sales growth, while Pfizer and Novo Nordisk hold smaller market shares. Investors are weighing Pfizer’s broader pharmaceutical portfolio and income stability against Lilly’s dominant market penetration and growth momentum.
2. Valuation Metrics and Dividend Yield
Pfizer trades at a modest P/E ratio relative to peers and offers a 6.3% dividend yield, compared with Lilly’s 0.6% yield. The higher income return appeals to yield-focused investors seeking durable cash flows amid growth uncertainties.
3. GLP-1 Development Risks
Pfizer’s GLP-1 candidates have faced recent trial delays and clinical hurdles, raising concerns about future market entry timing. Potential patent expirations and escalating competition underscore the need for successful late-stage results to justify a revaluation.